passages: 150
passages: document
passages: [ Improving wound healing after nose surgery by combined administration of xylometazoline and dexpanthenol ] . BACKGROUND The aim of this study was the examination of efficacy and tolerability of an application-form of the new combination of Xylometazoline with Dexpanthenol ( Nasic ) versus Xylometazoline alone . PATIENTS AND METHODS Randomized verum controlled parallel-group-comparison of two weeks treatment of a nasal-spray . 61 inpatients with the diagnosis Rhinitis following nasal operation were included in this study and 30 patients were treated with verum and placebo each . The assessment of nasal-breathing-resistance according to scores was defined as target-parameter . Confirmatory statistical analysis was carried out according to Wilcoxon-Mann-Whitney-U two-sided at alpha < or = 0.05 . MAIN OUTCOME MEASURE The superiority of the combination of Xylometazoline-Dexpanthenol nasal-spray versus Xylometazoline nasal spray could be proven for the target-parameter as clinically relevant and statistically significant . The clinically proven efficacy is emphasized by good tolerability of both treatments . Due to easy handling of the nasal-spray a good compliance was confirmed . CONCLUSION Distinct improvement of symptoms in patients following nasal operations underlines the efficacy of both medications . With respect to the tolerability therapy with the combination is more beneficial in comparison to the alternative therapy . The result of this controlled clinical study confirms that the combination Xylometazoline-Dexpanthenol is an enlargement and improvement of effective medicinal treatment of rhinitis following nasal operation in comparison to therapy with Xylometazoline alone .
entities: 151
entities: Intervention_Pharmacological
entities: xylometazoline
entities: 152
entities: Intervention_Pharmacological
entities: dexpanthenol ]
entities: 153
entities: Intervention_Pharmacological
entities: Xylometazoline
entities: 154
entities: Intervention_Pharmacological
entities: Dexpanthenol ( Nasic )
entities: 155
entities: Intervention_Pharmacological
entities: Xylometazoline
entities: 156
entities: Intervention_Pharmacological
entities: verum
entities: 157
entities: Intervention_Control
entities: placebo
entities: 158
entities: Intervention_Pharmacological
entities: Xylometazoline-Dexpanthenol
entities: 159
entities: Intervention_Pharmacological
entities: Xylometazoline
entities: 160
entities: Intervention_Pharmacological
entities: Xylometazoline-Dexpanthenol
entities: 161
entities: Intervention_Pharmacological
entities: Xylometazoline
entities: 162
entities: Outcome_Physical
entities: wound healing
entities: 163
entities: Outcome_Other
entities: efficacy
entities: 164
entities: Outcome_Other
entities: tolerability
entities: 165
entities: Outcome_Physical
entities: nasal-breathing-resistance according to scores
entities: 166
entities: Outcome_Other
entities: efficacy
entities: 167
entities: Outcome_Other
entities: tolerability
entities: 168
entities: Outcome_Mental
entities: compliance
entities: 169
entities: Outcome_Physical
entities: improvement
entities: 170
entities: Outcome_Other
entities: efficacy
entities: 171
entities: Outcome_Other
entities: tolerability
entities: 172
entities: Participant_Condition
entities: after nose surgery
entities: 173
entities: Participant_Sample-size
entities: 61
entities: 174
entities: Participant_Condition
entities: inpatients with the diagnosis Rhinitis following nasal operation
entities: 175
entities: Participant_Condition
entities: patients following nasal operations
entities: 176
entities: Participant_Condition
entities: rhinitis following nasal operation